Author(s): Foster M.; Carleton-Bland N.; Lee M.; Clark S.; Sarsam Z.; Wilby M.J.
Source: British Journal of Neurosurgery; 2018; vol. 32 (no. 1); p. 81
Publication Date: 2018
Publication Type(s): Conference Abstract
Abstract:Objectives: To quantify outcomes following transforaminal lumbar interbody fusion (TLIF). Design: Retrospective review of prospectively collected data. Subjects: Patients having TLIF between January 2012 and February 2016 in a single centre. Methods: Surgical details and patient reported outcomes (COMI-Back questionnaire) were extracted from our prospectively maintained electronic database. Minimal clinically important difference (MCID) was defined as a two-point decrease on the COMI score. The student’s t-test, and logistic regression were used to analyse data. Results: 159 patients were treated with TLIF between January 2012 and February 2016 (75F: 84M Median age 47 IQR 12). Surgery was without complication in 94% of cases. In comparison to pre-opera-tive COMI scores (mean 8.14), post-operative scores were significantly better at 3, 12 and 24 months (mean 5.96, 4.93, and 4.68 respectively; each p <0.01). Paired COMI scores improved between 3 and 12 months (p<0.01), and again between 12 and 24 months (p=0.01) Leg pain was improved in 76% at 3 months, 81% of patients at 12 months, and 80% at 24 months. Back pain improved in 71% at 3 months, 72% at 12 months and 75% at 24 months. MCID was seen in 46% at 3 months, 58% at 12 months, and 71% at 2 years. Age, ASA, BMI, and smoking status were not significantly correlated with two year MCID (p>0.05). Conclusions: TLIF in our unit is a safe procedure associated with improved COMI score, back pain and leg pain. Significant ongoing improvement was found to continue until two years post operatively.
Database: EMBASE